Skip to main content
OpenTrials
Completed

NCT Number: NCT04775264

Safety and Feasibility of Atrial Deganglionation as Adjunctive Therapy for AF

A prospective, single arm, multi-center exploratory study of safety and feasibility in the treatment of patients undergoing cardiothoracic surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Na Homolce Hospital, Prague, Czechia

Loading trial locations.

About this study

To assess the safety and feasibility of electroporation/Pulsed Electric Field (PEF) as a technology to achieve selective GP ablation. This treatment will be performed on 30 patients undergoing cardiothoracic surgery. Primary feasibility endpoint will be demonstration of ability to access and deliver Pulsed Electric Field energy to all of the targeted ablation sites.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age is between 18 and 70 years.
  • Scheduled for open-chest cardiothoracic surgery, for coronary artery bypass grafting.
  • Legally competent and willing to sign the informed consent.
  • Life expectancy of at least 2 years.

Exclusion criteria

  • • Previous cardiac surgery.
  • Prior pericardial interventions.
  • Prior pulmonary vein isolation (PVI).
  • Previous or existing pericarditis.
  • Persistent or long-standing persistent atrial fibrillation.
  • Indication for surgical ablation or PVI for atrial fibrillation.
  • Indication for concomitant surgical valve repair or replacement.
  • Indication for concomitant left atrial appendage (LAA) ligation or excision.
  • History of previous radiation therapy on the thorax.
  • History of previous thoracotomy.
  • Prior electrical or mechanical isolation of the Left Atrial Appendage (LAA).
  • The presence of LAA occlusion devices, coronary stents, prosthetic heart valves, pacemakers or implantable cardioverter defibrillators (ICDs).
  • Myocardial infarction within the previous 2 months.
  • NYHA (New York Heart Association) Class IV heart failure symptoms.
  • Left ventricular ejection fraction (LVEF) < 40%, measured by transthoracic echocardiography (TTE).
  • Left atrial (LA) diameter > 5.0 cm, measured by transthoracic echocardiography (TTE).
  • The presence of left atrial thrombus when examined by transoesophageal echocardiography (TEE).
  • The presence of AF attributable to non-cardiovascular causes such as thyroid disease, electrolyte imbalance/dehydration or other reversible causes.
  • Active infection or sepsis as evidenced by increased white blood cell count, elevated CRP (C-Reactive Protein) or temperature > 38.5°C.
  • Known or documented carotid stenosis > 80%
  • Stroke or transient ischemic attack within the previous 6 months.
  • Known or documented epilepsy.
  • Pregnancy or child-bearing potential without adequate contraception.
  • Circumstances that prevent follow-ups.
  • Drug abuse.
  • Patients cannot be enrolled in another clinical study

Treatment and study plan

Pulsed Electric Field Ablation

Procedure

Catheter ablation of Ganglionated Plexi (GP) structures on the epicardial surface of the heart during cardiothoracic surgery

Primary outcomes

  1. Number of Participants With Device-related Primary Safety Adverse Events

    Time frame: 30 days

    Primary Safety Adverse Events include:

    • Atrial perforation or excessive bleeding (excessive bleeding is defined as bleeding which requires any blood transfusion).
    • Pericarditis
    • Pericardial effusion
    • Cardiac tamponade (if either surgical or percutaneous drainage is required).
    • Constrictive pericarditis, requiring re-operation.
    • Newly developed sinus node dysfunction.
    • Newly developed first, second or third degree atrioventricular (AV) block
    • Vasovagal reactions during hospital stay
    • Ventricular fibrillation
  2. Number of Participants in Which Pulsed Electric Field Was Successfully Delivered to All Target Sites on the Epicardial Surface of the Heart.

    Time frame: Intraprocedural - during the ablation procedure. Within 1 hour of sternotomy.

    Confirmation of catheter access and delivery of pulsed electric field energy to each of the targeted ablation sites on the epicardial surface of the heart.

Sponsors and collaborators

Lead sponsor

Atrian Medical Ltd.

Industry

Registry information

Official study title

Safety and Feasibility of Atrial Deganglionation as Adjunctive Therapy for Atrial Fibrillation

Acronym: Neural-AF

Important dates

Study start
2021
Primary completion
2022
Study completion
2023
First posted
Mar 1, 2021
Registry last updated
Feb 9, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.